An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis

Virology

Volumn 295, Issue 2, 2002, Pages 272-283

  Girard, Sophie ^a   Shalhoub, Philip ^a   Lescure, Pascal ^a   Sabile, Abdelmajid ^a   Misek, David E ^b   Hanash, Samir ^a   Bréchot, Christian ^b   Beretta, Laura ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSERM   (France)

Author keywords

HCV; IFN ; IL 8; Microarray; NS5A

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 8; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN NS5A;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UNINDEXED SEQUENCE;

HEPATITIS C VIRUS;

EID: 0036067898     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1373     Document Type: Article

References (71)

1. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins
2. Epidemiology of hepatitis C
3. Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis
4. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients
5. Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C
6. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
7. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions
8. Cytokine (tumor necrosis actor, IL-6 and IL-8) production by respiratory syncitial virus-infected human alveolar macrophages
9. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis
10. Interleukin-8 production by cystic fibrosis nasal epithelial cells after tumor necrosis factor-alpha and respiratory syncitial virus stimulation
11. Hepatitis C virus: Molecular biology and genetic variability
12. Requirement of a novel upstream response element in respiratory syncitial virus-induced IL-8 gene expression
13. Interferon-inducible Myc/STAT-interacting protein Nmi associates with IFP 35 into a high molecular mass complex and inhibits proteasome-mediated degradation of IFP 35
14. Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis
15. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays
16. Hepatitis C and hepatocellular carcinoma
17. Inhibition of IL-4-inducible gene expression in human monocytes by type I and type II interferons
18. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region
19. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
20. Respiratory syncitial virus increases IL-8 gene expression and protein release in A549 cells
21. Inhibition of viral replication reverses respiratory syncitial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells
22. Transcriptional induction of the p69 isoform of 2′,5′-oligoadenylate synthetase by interferon-beta and interferon-gamma involves three regulatory elements and interferon-stimulated gene factor 3
23. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
24. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
25. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
26. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon
27. Molecular cloning of a new interferon-induced PML nuclear body-associated protein
28. Expression and identification of hepatitis C virus polyprotein cleavage products
29. Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy
30. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2
31. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
32. Identification of 69-kd and 100-kd forms of 2-5A synthetase in interferon-treated human cells by specific monoclonal antibodies
33. The human 2′,5′-oligoadenylate synthetase-like gene (OASL) encoding the interferon-induced 56-kDa protein maps to chromosome 12q24.2 in the proximity of the 2′,5′-OAS locus
34. Human herpesvirus 6 induces II-8 gene expression in human hepatoma cell line, HepG2
35. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis
36. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer
37. The α chemokine, interleukin 8, inhibits the antiviral action of interferon α
38. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-α therapy in French patients
39. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection
40. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
41. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice
42. 69-kDa and 100-kDa isoforms of interferon-induced (2′,5′)oligoadenylate synthetase exhibit differential catalytic parameters
43. The expression of both domains of the 69/71 kDa 2′,5′ oligoadenylate synthetase generates a catalytically active enzyme and mediates an anti-viral response
44. Induction of interleukin (IL-8) gene expression by respiratory syncitial virus involves activation of nuclear factor (NF)-kappaB and NF-IL-6
45. Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor-kappaB in respiratory syncitial virus-induced interleukin-8 gene expression in airway epithelium
46. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
47. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
48. Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cells
49. Potential involvement of II-8 in the pathogenesis of human cytomegalovirus infection
50. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy
51. Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms
52. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
53. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
54. Expression of hepatitis C virus NS5A natural mutants in an hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner
55. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication
56. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response
57. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy
58. The human 2′,5′-oligoadenylate synthetase family: Interferon-induced proteins with unique enzymatic properties
59. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element
60. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
61. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
62. Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome
63. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon
64. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon α
65. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection
66. STAT family of transcription factors in cytokine-mediated biological responses
67. Maximal induction of p69 2′,5′-oligoadenylate synthetase in Daudi cells requires cooperation between an ISRE and two IRF-1-like elements
68. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for non-structural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection
69. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response
70. Mutations in the non-structural 5A gene of European hepatitis C virus isolates and response to interferon α
71. Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface